(Q38246355)

1 September 2017

title

10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children (English)

1 reference

1 September 2017

main subject

Haemophilus influenzae

object named as

haemophilus influenzae

1 reference

1

Greg L Plosker

1 reference

1 September 2017

publication date

1 October 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

16

1 reference

1 September 2017

issue

5

1 reference

1 September 2017

page(s)

425-444

1 reference

https://scigraph.springernature.com/pub.10.1007/s40272-014-0089-x

1 September 2017

exact match

0 references

cites work

Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Thymus-independent and thymus-dependent responses to polysaccharide antigens

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

21 January 2018

12 December 2020

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, contr

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic para

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Perinatal Risk Factors for Hospitalization for Pneumococcal Disease in Childhood: A Population-Based Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0089-X

Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized co

21 January 2018

1 reference

12 December 2020

Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012.

1 reference

12 December 2020

Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.

1 reference

12 December 2020

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway

1 reference

12 December 2020

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants

1 reference

12 December 2020

Prevention of invasive pneumococcal disease: new evidence

1 reference

12 December 2020

Further evidence for the effectiveness of PCV10 against Streptococcus pneumoniae serotype 19A

1 reference

12 December 2020

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

1 reference

12 December 2020

Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age

1 reference

12 December 2020

Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine

1 reference

12 December 2020

Pneumococcal vaccines WHO position paper--2012

1 reference

12 December 2020

Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines

1 reference

12 December 2020

Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage

1 reference

12 December 2020

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina

1 reference

12 December 2020

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

1 reference

12 December 2020

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.

1 reference

12 December 2020

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

1 reference

12 December 2020

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model

1 reference

12 December 2020

10.1007/S40272-014-0089-X

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1012509042

0 references

1 reference